JP2023543215A5 - - Google Patents

Info

Publication number
JP2023543215A5
JP2023543215A5 JP2023518754A JP2023518754A JP2023543215A5 JP 2023543215 A5 JP2023543215 A5 JP 2023543215A5 JP 2023518754 A JP2023518754 A JP 2023518754A JP 2023518754 A JP2023518754 A JP 2023518754A JP 2023543215 A5 JP2023543215 A5 JP 2023543215A5
Authority
JP
Japan
Prior art keywords
modified
nucleosides
oligonucleotide
nucleoside
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543215A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/051822 external-priority patent/WO2022066956A1/en
Publication of JP2023543215A publication Critical patent/JP2023543215A/ja
Publication of JP2023543215A5 publication Critical patent/JP2023543215A5/ja
Pending legal-status Critical Current

Links

JP2023518754A 2020-09-24 2021-09-23 Apoeの発現を低減するための化合物及び方法 Pending JP2023543215A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063083006P 2020-09-24 2020-09-24
US63/083,006 2020-09-24
PCT/US2021/051822 WO2022066956A1 (en) 2020-09-24 2021-09-23 Compounds and methods for reducing apoe expression

Publications (2)

Publication Number Publication Date
JP2023543215A JP2023543215A (ja) 2023-10-13
JP2023543215A5 true JP2023543215A5 (cg-RX-API-DMAC7.html) 2024-10-21

Family

ID=80846882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518754A Pending JP2023543215A (ja) 2020-09-24 2021-09-23 Apoeの発現を低減するための化合物及び方法

Country Status (4)

Country Link
US (1) US20230357770A1 (cg-RX-API-DMAC7.html)
EP (1) EP4216964A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023543215A (cg-RX-API-DMAC7.html)
WO (1) WO2022066956A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4466357A2 (en) * 2022-01-23 2024-11-27 Regeneron Pharmaceuticals, Inc. Methods of improving health with apolipoprotein e (apoe) inhibitors
EP4665850A2 (en) * 2023-02-13 2025-12-24 SciNeuro Therapeutics Inc. Oligonucleotides for modulating apolipoprotein e (apoe) expression and methods of use thereof
WO2025240846A1 (en) * 2024-05-17 2025-11-20 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating apoe expression
WO2026109696A1 (en) * 2024-11-22 2026-05-28 Ribocure Pharmaceuticals Ab Oligonucleotide, oligonucleotide conjugate and composition and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517644B1 (en) * 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
JP2006510341A (ja) * 2002-02-27 2006-03-30 バイエル・ヘルスケア・アクチェンゲゼルシャフト 有害薬剤反応および薬剤効力を予測する単一ヌクレオチド多型
WO2015187989A1 (en) * 2014-06-04 2015-12-10 Isis Pharmaceuticals, Inc. Antisense compounds targeting apolipoprotein e receptor 2
EP3191578B1 (en) * 2014-09-12 2020-11-04 Whitehead Institute for Biomedical Research Cells expressing apolipoprotein e and uses thereof
US11015204B2 (en) * 2017-05-31 2021-05-25 Arcturus Therapeutics, Inc. Synthesis and structure of high potency RNA therapeutics
US10517889B2 (en) * 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
WO2020176771A1 (en) * 2019-02-27 2020-09-03 Ionis Pharmaceuticals, Inc. Modulators of malat1 expression
JP2022540446A (ja) * 2019-07-10 2022-09-15 ロックアネイビオ, インコーポレイテッド Rna標的ノックダウン及び置換の組成物及び使用方法
CN110257510A (zh) * 2019-08-06 2019-09-20 江苏贝格尔生物医药有限公司 一种检测apoe基因多态性的引物和探针及试剂盒
JP7844347B2 (ja) * 2020-04-27 2026-04-13 アルナイラム ファーマシューティカルズ, インコーポレイテッド アポリポタンパク質E(ApoE)iRNA剤組成物およびその使用方法

Similar Documents

Publication Publication Date Title
JP2022518929A5 (cg-RX-API-DMAC7.html)
JP7477569B2 (ja) タウ発現を低減するための化合物及び方法
JP3926840B2 (ja) 遺伝子発現をダウンレギュレートするための2’−置換オリゴヌクレオチドの使用
JP2023536472A5 (cg-RX-API-DMAC7.html)
JP2022515193A5 (cg-RX-API-DMAC7.html)
JP2021530204A5 (cg-RX-API-DMAC7.html)
JP7748500B2 (ja) トリループを含む二本鎖核酸インヒビター分子
JP2022509625A5 (cg-RX-API-DMAC7.html)
JP2025000693A (ja) Appの発現を低減するための化合物及び方法
JP2022527105A5 (cg-RX-API-DMAC7.html)
JP2022520986A5 (cg-RX-API-DMAC7.html)
JP2019525918A5 (cg-RX-API-DMAC7.html)
JPH08502040A (ja) ハイブリッド オリゴヌクレオチド ホスホロチオエート
CA3238865A1 (en) Composition and methods for inhibiting expression of angiotensinogen (agt) protein
JP7696466B2 (ja) Smn2を調節するための化合物及び方法
JP2019534009A5 (cg-RX-API-DMAC7.html)
JP2024516356A5 (cg-RX-API-DMAC7.html)
JP2023528755A5 (cg-RX-API-DMAC7.html)
CN108884462A (zh) 单链寡核苷酸
CN116322707A (zh) 用于调节scn2a的化合物和方法
JP2024545052A (ja) 修飾骨格化学を有するスプライススイッチャーアンチセンスオリゴヌクレオチド
CN113795581A (zh) 具有缩短的有义链的双链核酸抑制剂分子
JP2022530678A5 (cg-RX-API-DMAC7.html)
JP2023543215A (ja) Apoeの発現を低減するための化合物及び方法
JP2024523363A5 (cg-RX-API-DMAC7.html)